Urbifen 50

Urbifen 5050mg

Type:10 Tablets

Generic Name:Flurbiprofen

Manufacturer:General Pharmaceuticals Ltd.

Price:35.00

Ad

Indication

Dysmenorrhoea, Sore throat, Ocular inflammation, Pain and inflammation associated w/ musculoskeletal and joint disorders, Prophylaxis of miosis during ocular surgery

Administration

Should be taken with food.

Adult Dose

Oral Pain and inflammation Adult: 150-200 mg daily in divided doses, increased to 300 mg daily in acute or severe conditions if necessary. Dysmenorrhoea Adult: Initially, 100 mg followed by 50-100 mg 4-6 hrly. Max: 300 mg daily. Rheumatoid Arthritis, Osteoarthritis 200-300 mg/day divided q6-12hr PO, not to exceed 100 mg/dose or 300 mg/day

Child Dose

<12 years: Not recommended

Renal Dose

Renal Impairment Severe Impairment: Not recommended

Contraindication

Peptic ulcer, GI haemorrhage, asthma, bronchospasm, rhinitis, angioedema, hypersensitivity; aspirin intolerance; pregnancy (3rd trimester); lactation.

Mode of Action

Flurbiprofen inhibits prostaglandin synthesis by decreasing the activity of cyclooxygenase resulting in reduced prostaglandin levels. It is also a potent inhibitor of platelet aggregation.

Precaution

Patients w/ known CV disease or risk factors for CV disease, fluid retention. Hepatic and renal impairment. Lactation. Lactation: excreted in breast milk; not recommended

Side Effect

Oedema, abdominal pain, constipation, diarrhoea, dyspepsia/heartburn, liver enzyme elevations, flatulence, nausea, vomiting, wt change, headache, nervousness, CNS stimulation (e.g. anxiety), CNS inhibition (e.g. somnolence), rhinitis, vision changes, dizziness/vertigo, tinnitus, signs and symptoms of UTI, rash. Ocular hyperaemia, eye irritation, fibrosis, miosis, mydriasis. Potentially Fatal: GI bleeding, ulceration and perforation, jaundice, fulminant hepatitis, liver necrosis, hepatic failure.

Pregnancy Category Note

Pregnancy Category: C; avoid in late pregnancy Lactation: excreted in breast milk; not recommended

Interaction

Reduced antihypertensive effect of ACE inhibitors, angiotensin II receptor antagonists and ?-blockers. Slight reduction in blood glucose concentration in patients w/ DM receiving certain antidiabetic agents (e.g. glyburide, metformin). Reduced diuretic effect of furosemide and thiazides. May increase toxicity of lithium and methotrexate. May increase risk of bleeding w/ antiplatelets, anticoagulants, SSRIs, corticosteroids.

Alternative brand of Urbifen 50